Pangali EV/EBITDA: Agios Pharmaceuticals Inc (AGIO)

The historical EV/EBITDA level for Agios Pharmaceuticals (AGIO) based on the GURU.Markets chart remains around 0.00. The niche market for orphan diseases and regulatory pressure on therapy costs create certain risks. The business model is based on high pricing for rare drugs with minimal production costs, while dependence on a single approved product slows the path to profitability.

This ratio compares the total value of assets and liabilities with operating income before depreciation and amortization, allowing for an assessment of the business's real value regardless of tax policy and debt structure. In the case of Agios Pharmaceuticals (AGIO), this calculation is critical for analyzing capital intensity during the implementation of orphan drugs, which clearly reflects the change in the EV/EBITDA multiple within the context of cash reserve stability.